Why the study?
Does alirocumab reduce the risk of recurrent ischemic cardiovascular events in patients who have had an acute coronary syndrome and are receiving intensive statin therapy?
Does alirocumab reduce the risk of recurrent ischemic cardiovascular events in patients who have had an acute coronary syndrome and are receiving intensive statin therapy?
The applicability of the ODYSSEY OUTCOMES trial results may be limited because very few patients were on background ezetimibe therapy, contrary to current cholesterol management guidelines.
To the Editor: In the ODYSSEY OUTCOMES trial, Schwartz et al. (Nov. 29 issue)(1) report that the proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitor alirocumab could reduce the risk of recurrent ischemic cardiovascular events in patients who have had an acute coronary syndrome and are receiving intensive statin therapy. However, because less than 3% of these patients were receiving ezetimibe in addition to statin therapy, the trial might not support the use of alirocumab in similar patients in clinical practice. According to the latest guideline on the management of cholesterol,(2) ezetimibe should be added to statin therapy (given at the . . .
No takes yet. Share an insight, caveat, or question.
A 2019 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: